Trabecular Bone Score As a Skeletal Fragility Index in Acromegaly Patients

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2015 Oct 9

PMID 26446771

Citations 26

Authors

A R Hong

J H Kim

S W Kim

S Y Kim

C S Shin

Affiliations

Soon will be listed here.

Abstract

Summary: Lumbar spine trabecular bone score (TBS) was significantly decreased in active acromegaly patients. TBS may be useful to assess the skeletal fragility in acromegaly in which bone mineral density (BMD) is not sufficient to represent bone strength and explain the high incidence of fragility fractures in acromegaly patients.

Introduction: Although the data on BMD are controversial, patients with acromegaly have an increased risk of fragility fracture. We examined the lumbar spine TBS to explain the skeletal deterioration in acromegaly patients.

Methods: We included 14 men and 19 women acromegaly patients who underwent dual-energy X-ray absorptiometry at the time of diagnosis from 2000 to 2014 at Seoul National University Hospital. Ninety-nine age-, sex- and body mass index-matched controls were recruited. Biochemical parameters, lumbar spine TBS, and BMD at all sites were measured. Gonadal status was evaluated at diagnosis.

Results: Lumbar spine TBS was lower in acromegaly patients than in controls in both genders (1.345 ± 0.121 vs. 1.427 ± 0.087, P = 0.005 in men; 1.356 ± 0.082 vs. 1.431 ± 0.071, P = 0.001 in women). In contrast, BMD at all sites did not differ between the two groups. Hypogonadal acromegaly patients (men, n = 9; women, n = 12) had lower TBS values compared with controls both in men and women (all P < 0.05), although BMD at all sites were similar for the two groups. In eugonadal acromegaly patients, lumbar spine TBS was lower than in women controls only (P = 0.041).

Conclusions: Skeletal microarchitecture was deteriorated in acromegaly patients as assessed by TBS, which seems to be a consequence of growth hormone excess as well as hypogonadism, especially in women.

Citing Articles

Novel approach to bone comorbidity in resistant acromegaly.

Frara S, Acanfora M, Franzese V, Brandi M, Losa M, Giustina A Pituitary. 2024; 27(6):813-823.

PMID: 39570564 DOI: 10.1007/s11102-024-01468-y.

Impact of medical therapy for hormone-secreting Pituitary tumors on bone.

Freda P Pituitary. 2024; 27(6):860-873.

PMID: 38967763 DOI: 10.1007/s11102-024-01421-z.

Acromegaly and Bone: An Update.

Giustina A Endocrinol Metab (Seoul). 2024; 38(6):655-666.

PMID: 38164073 PMC: 10764988. DOI: 10.3803/EnM.2023.601.

Persistent Deficits in Bone Quality in Treated Acromegaly: Evidence From Assessments of Microstructure.

Kuker A, Agarwal S, Shane E, Cohen A, Nickolas T, Stein E J Endocr Soc. 2023; 7(10):bvad121.

PMID: 37809053 PMC: 10553518. DOI: 10.1210/jendso/bvad121.

Differences between bone health parameters in adults with acromegaly and growth hormone deficiency: A systematic review.

Freda P Best Pract Res Clin Endocrinol Metab. 2023; 37(6):101824.

PMID: 37798201 PMC: 10843107. DOI: 10.1016/j.beem.2023.101824.

References

Monson J, Drake W, Carroll P, Weaver J, Rodriguez-Arnao J, Savage M . Influence of growth hormone on accretion of bone mass. Horm Res. 2002; 58 Suppl 1:52-6. DOI: 10.1159/000064765. View

Wuster C, Abs R, Bengtsson B, Bennmarker H, Feldt-Rasmussen U, Monson J . The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. . J Bone Miner Res. 2001; 16(2):398-405. DOI: 10.1359/jbmr.2001.16.2.398. View

Tutuncu N, Erbas T . Factors associated with bone metabolism in acromegalic patients: hypogonadism and female gender. Exp Clin Endocrinol Diabetes. 2004; 112(6):328-32. DOI: 10.1055/s-2004-820913. View

Zgliczynski W, Kochman M, Misiorowski W, Zdunowski P . In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender. Neuro Endocrinol Lett. 2007; 28(5):621-8. View

Nicks K, Amin S, Atkinson E, Riggs B, Melton 3rd L, Khosla S . Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res. 2011; 27(3):637-44. PMC: 3636571. DOI: 10.1002/jbmr.1468. View

Bolanowski M, Daroszewski J, Medras M, Zadrozna-Sliwka B . Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab. 2005; 24(1):72-8. DOI: 10.1007/s00774-005-0649-9. View

Baroncelli G, Bertelloni S, Sodini F, Saggese G . Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J Pediatr Endocrinol Metab. 2003; 16 Suppl 2:327-35. View

Bousson V, Bergot C, Sutter B, Levitz P, Cortet B . Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporos Int. 2011; 23(5):1489-501. DOI: 10.1007/s00198-011-1824-6. View

Melmed S, Colao A, Barkan A, Molitch M, Grossman A, Kleinberg D . Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009; 94(5):1509-17. DOI: 10.1210/jc.2008-2421. View

10.

Kalder M, Hans D, Kyvernitakis I, Lamy O, Bauer M, Hadji P . Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer. J Clin Densitom. 2013; 17(1):66-71. DOI: 10.1016/j.jocd.2013.03.003. View

11.

Kayath M, Vieira J . Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int. 1997; 7(3):226-30. DOI: 10.1007/BF01622293. View

12.

Ueland T, Ebbesen E, Thomsen J, Mosekilde L, Brixen K, Flyvbjerg A . Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Invest. 2002; 32(2):122-8. DOI: 10.1046/j.1365-2362.2002.00944.x. View

13.

Madeira M, Vieira Neto L, Torres C, de Mendonca L, Gadelha M, de Farias M . Vertebral fracture assessment in acromegaly. J Clin Densitom. 2012; 16(2):238-43. DOI: 10.1016/j.jocd.2012.06.002. View

14.

Madeira M, Vieira Neto L, Paranhos Neto F, Barbosa Lima I, de Mendonca L, Gadelha M . Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2013; 98(4):1734-41. DOI: 10.1210/jc.2012-4073. View

15.

. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab. 2004; 89(7):3099-102. DOI: 10.1210/jc.2003-031138. View

16.

Seeman E . Periosteal bone formation--a neglected determinant of bone strength. N Engl J Med. 2003; 349(4):320-3. DOI: 10.1056/NEJMp038101. View

17.

Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R . Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2014; 100(2):384-94. DOI: 10.1210/jc.2014-2937. View

18.

Diamond T, Nery L, Posen S . Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med. 1989; 111(7):567-73. DOI: 10.7326/0003-4819-111-7-567. View

19.

Giustina A, Mazziotti G, Canalis E . Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008; 29(5):535-59. PMC: 2726838. DOI: 10.1210/er.2007-0036. View

20.

Katznelson L, Laws Jr E, Melmed S, Molitch M, Murad M, Utz A . Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(11):3933-51. DOI: 10.1210/jc.2014-2700. View